Listed

Biocryst Pharmaceuticals Inc

BCRXNasdaqCIK 882796HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$218.3m, Q2 FY2026
Operating income$98.5m, Q2 FY2026
Net income$78.4m, Q2 FY2026
Biocryst Pharmaceuticals Inc, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m86.7Revenue, Q3 FY2023, three months to 2023-09-30$86.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure93.4Revenue, Q4 FY2023, three months to 2023-12-31$93.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure92.8Revenue, Q1 FY2024, three months to 2024-03-31$92.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure109Revenue, Q2 FY2024, three months to 2024-06-30$109.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure117Revenue, Q3 FY2024, three months to 2024-09-30$117.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure132Revenue, Q4 FY2024, three months to 2024-12-31$131.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure146Revenue, Q1 FY2025, three months to 2025-03-31$145.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure163Revenue, Q2 FY2025, three months to 2025-06-30$163.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure159Revenue, Q3 FY2025, three months to 2025-09-30$159.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure407Revenue, Q4 FY2025, three months to 2025-12-31$406.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure156Revenue, Q1 FY2026, three months to 2026-03-31$156.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure218Revenue, Q2 FY2026, three months to 2026-06-30$218.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Cost of revenue$m1.1Cost of revenue, Q3 FY2023, three months to 2023-09-30$1.1m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure1.6Cost of revenue, Q4 FY2023, three months to 2023-12-31$1.6m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure1.3Cost of revenue, Q1 FY2024, three months to 2024-03-31$1.3m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure1.7Cost of revenue, Q2 FY2024, three months to 2024-06-30$1.7m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure3.2Cost of revenue, Q3 FY2024, three months to 2024-09-30$3.2m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure6.1Cost of revenue, Q4 FY2024, three months to 2024-12-31$6.1m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure4.6Cost of revenue, Q1 FY2025, three months to 2025-03-31$4.6m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure2.8Cost of revenue, Q2 FY2025, three months to 2025-06-30$2.8m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure2.2Cost of revenue, Q3 FY2025, three months to 2025-09-30$2.2m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure9.5Cost of revenue, Q4 FY2025, three months to 2025-12-31$9.5m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure5.4Cost of revenue, Q1 FY2026, three months to 2026-03-31$5.4m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure3.8Cost of revenue, Q2 FY2026, three months to 2026-06-30$3.8m. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Research and development$m46.9Research and development, Q3 FY2023, three months to 2023-09-30$46.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure70.1Research and development, Q4 FY2023, three months to 2023-12-31$70.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure46.5Research and development, Q1 FY2024, three months to 2024-03-31$46.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure37.6Research and development, Q2 FY2024, three months to 2024-06-30$37.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure41.1Research and development, Q3 FY2024, three months to 2024-09-30$41.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure49.4Research and development, Q4 FY2024, three months to 2024-12-31$49.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure37.3Research and development, Q1 FY2025, three months to 2025-03-31$37.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure43.4Research and development, Q2 FY2025, three months to 2025-06-30$43.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure44.6Research and development, Q3 FY2025, three months to 2025-09-30$44.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure40.9Research and development, Q4 FY2025, three months to 2025-12-31$40.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure60.3Research and development, Q1 FY2026, three months to 2026-03-31$60.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure52.0Research and development, Q2 FY2026, three months to 2026-06-30$52.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Selling, general and administrative$m50.6Selling, general and administrative, Q3 FY2023, three months to 2023-09-30$50.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure64.6Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$64.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure59.5Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$59.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure61.2Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$61.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure65.1Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$65.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure80.5Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$80.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure82.5Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$82.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure87.4Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$87.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure83.0Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$83.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure95.8Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$95.8m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure94.6Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$94.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure64.0Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$64.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Operating income$m(11.9)Operating income, Q3 FY2023, three months to 2023-09-30−$11.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure(42.7)Operating income, Q4 FY2023, three months to 2023-12-31−$42.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(14.5)Operating income, Q1 FY2024, three months to 2024-03-31−$14.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure8.8Operating income, Q2 FY2024, three months to 2024-06-30$8.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure7.7Operating income, Q3 FY2024, three months to 2024-09-30$7.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure(4.5)Operating income, Q4 FY2024, three months to 2024-12-31−$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure21.2Operating income, Q1 FY2025, three months to 2025-03-31$21.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure29.8Operating income, Q2 FY2025, three months to 2025-06-30$29.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure29.6Operating income, Q3 FY2025, three months to 2025-09-30$29.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure260Operating income, Q4 FY2025, three months to 2025-12-31$260.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(702)Operating income, Q1 FY2026, three months to 2026-03-31−$701.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure98.5Operating income, Q2 FY2026, three months to 2026-06-30$98.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Interest expense$m27.3Interest expense, Q3 FY2023, three months to 2023-09-30$27.3m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-08, accession 0001628280-23-037847.Report this figure24.6Interest expense, Q4 FY2023, three months to 2023-12-31$24.6m. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-02-27, accession 0001628280-24-007205. Derived: 12-month figure less the 9-month figure.Report this figure24.5Interest expense, Q1 FY2024, three months to 2024-03-31$24.5m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-07, accession 0001628280-24-021069.Report this figure24.7Interest expense, Q2 FY2024, three months to 2024-06-30$24.7m. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-06, accession 0001628280-24-035170.Report this figure24.8Interest expense, Q3 FY2024, three months to 2024-09-30$24.8m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure24.4Interest expense, Q4 FY2024, three months to 2024-12-31$24.4m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure23.5Interest expense, Q1 FY2025, three months to 2025-03-31$23.5m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure21.6Interest expense, Q2 FY2025, three months to 2025-06-30$21.6m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure19.7Interest expense, Q3 FY2025, three months to 2025-09-30$19.7m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure14.1Interest expense, Q4 FY2025, three months to 2025-12-31$14.1m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure19.8Interest expense, Q1 FY2026, three months to 2026-03-31$19.8m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure21.7Interest expense, Q2 FY2026, three months to 2026-06-30$21.7m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Income tax$m0.3Income tax, Q3 FY2023, three months to 2023-09-30$330.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure(1.4)Income tax, Q4 FY2023, three months to 2023-12-31−$1.4m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure0.4Income tax, Q1 FY2024, three months to 2024-03-31$365.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure0.2Income tax, Q2 FY2024, three months to 2024-06-30$172.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure0.6Income tax, Q3 FY2024, three months to 2024-09-30$586.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure0.8Income tax, Q4 FY2024, three months to 2024-12-31$804.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure0.7Income tax, Q1 FY2025, three months to 2025-03-31$726.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure1.4Income tax, Q2 FY2025, three months to 2025-06-30$1.4m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure(0.8)Income tax, Q3 FY2025, three months to 2025-09-30−$769.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure2.2Income tax, Q4 FY2025, three months to 2025-12-31$2.2m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure1.0Income tax, Q1 FY2026, three months to 2026-03-31$1.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure1.1Income tax, Q2 FY2026, three months to 2026-06-30$1.1m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Net income$m(36.1)Net income, Q3 FY2023, three months to 2023-09-30−$36.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure(61.7)Net income, Q4 FY2023, three months to 2023-12-31−$61.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(35.4)Net income, Q1 FY2024, three months to 2024-03-31−$35.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure(12.7)Net income, Q2 FY2024, three months to 2024-06-30−$12.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure(14.0)Net income, Q3 FY2024, three months to 2024-09-30−$14.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure(26.8)Net income, Q4 FY2024, three months to 2024-12-31−$26.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure0.0Net income, Q1 FY2025, three months to 2025-03-31$32.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure5.1Net income, Q2 FY2025, three months to 2025-06-30$5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure12.9Net income, Q3 FY2025, three months to 2025-09-30$12.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure246Net income, Q4 FY2025, three months to 2025-12-31$245.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(722)Net income, Q1 FY2026, three months to 2026-03-31−$721.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure78.4Net income, Q2 FY2026, three months to 2026-06-30$78.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Diluted EPS$ per share(0.19)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figurenot reported(0.17)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure(0.06)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure(0.07)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figurenot reported0.00Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure0.02Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure0.06Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figurenot reported(2.98)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$2.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure0.30Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Basic EPS$ per share(0.19)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figurenot reported(0.17)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure(0.06)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure(0.07)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figurenot reported0.00Basic EPS, Q1 FY2025, three months to 2025-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure0.02Basic EPS, Q2 FY2025, three months to 2025-06-30$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure0.06Basic EPS, Q3 FY2025, three months to 2025-09-30$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figurenot reported(2.98)Basic EPS, Q1 FY2026, three months to 2026-03-31−$2.98 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure0.31Basic EPS, Q2 FY2026, three months to 2026-06-30$0.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure

Balance sheet

Cash and equivalents$155.0m, Q2 FY2026
Long-term debt$395.4m, Q2 FY2026
Shareholders' equity−$454.3m, Q2 FY2026
Biocryst Pharmaceuticals Inc, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m151Cash and equivalents, Q3 FY2023, at 2023-09-30$150.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-08, accession 0001628280-23-037847.Report this figure111Cash and equivalents, FY2023, at 2023-12-31$110.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure84.3Cash and equivalents, Q1 FY2024, at 2024-03-31$84.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure78.4Cash and equivalents, Q2 FY2024, at 2024-06-30$78.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure96.8Cash and equivalents, Q3 FY2024, at 2024-09-30$96.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure105Cash and equivalents, FY2024, at 2024-12-31$104.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure105Cash and equivalents, Q1 FY2025, at 2025-03-31$105.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure88.0Cash and equivalents, Q2 FY2025, at 2025-06-30$88.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure84.1Cash and equivalents, Q3 FY2025, at 2025-09-30$84.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure89.7Cash and equivalents, FY2025, at 2025-12-31$89.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure172Cash and equivalents, Q1 FY2026, at 2026-03-31$171.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure155Cash and equivalents, Q2 FY2026, at 2026-06-30$155.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Current assets$m502Current assets, Q3 FY2023, at 2023-09-30$502.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-08, accession 0001628280-23-037847.Report this figure496Current assets, FY2023, at 2023-12-31$496.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-25, accession 0001628280-25-007715.Report this figure447Current assets, Q1 FY2024, at 2024-03-31$447.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001628280-24-021069.Report this figure363Current assets, Q2 FY2024, at 2024-06-30$363.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0001628280-24-035170.Report this figure427Current assets, Q3 FY2024, at 2024-09-30$427.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure422Current assets, FY2024, at 2024-12-31$422.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure410Current assets, Q1 FY2025, at 2025-03-31$410.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure398Current assets, Q2 FY2025, at 2025-06-30$398.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure356Current assets, Q3 FY2025, at 2025-09-30$355.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure404Current assets, FY2025, at 2025-12-31$404.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure374Current assets, Q1 FY2026, at 2026-03-31$373.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure485Current assets, Q2 FY2026, at 2026-06-30$484.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Total assets$m523Total assets, Q3 FY2023, at 2023-09-30$522.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-08, accession 0001628280-23-037847.Report this figure517Total assets, FY2023, at 2023-12-31$517.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-25, accession 0001628280-25-007715.Report this figure468Total assets, Q1 FY2024, at 2024-03-31$467.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001628280-24-021069.Report this figure472Total assets, Q2 FY2024, at 2024-06-30$472.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0001628280-24-035170.Report this figure491Total assets, Q3 FY2024, at 2024-09-30$491.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure490Total assets, FY2024, at 2024-12-31$490.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure480Total assets, Q1 FY2025, at 2025-03-31$480.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure457Total assets, Q2 FY2025, at 2025-06-30$457.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure446Total assets, Q3 FY2025, at 2025-09-30$446.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure514Total assets, FY2025, at 2025-12-31$514.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure465Total assets, Q1 FY2026, at 2026-03-31$465.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure558Total assets, Q2 FY2026, at 2026-06-30$557.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Current liabilities$m90.8Current liabilities, Q3 FY2023, at 2023-09-30$90.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-08, accession 0001628280-23-037847.Report this figure150Current liabilities, FY2023, at 2023-12-31$150.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-25, accession 0001628280-25-007715.Report this figure120Current liabilities, Q1 FY2024, at 2024-03-31$119.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001628280-24-021069.Report this figure129Current liabilities, Q2 FY2024, at 2024-06-30$129.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0001628280-24-035170.Report this figure154Current liabilities, Q3 FY2024, at 2024-09-30$153.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure160Current liabilities, FY2024, at 2024-12-31$160.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure140Current liabilities, Q1 FY2025, at 2025-03-31$139.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure177Current liabilities, Q2 FY2025, at 2025-06-30$177.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure190Current liabilities, Q3 FY2025, at 2025-09-30$190.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure196Current liabilities, FY2025, at 2025-12-31$196.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure195Current liabilities, Q1 FY2026, at 2026-03-31$195.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure209Current liabilities, Q2 FY2026, at 2026-06-30$208.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Total liabilities$mnot reported972Total liabilities, FY2023, at 2023-12-31$972.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-25, accession 0001628280-25-007715.Report this figurenot reportednot reported960Total liabilities, Q3 FY2024, at 2024-09-30$959.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure966Total liabilities, FY2024, at 2024-12-31$966.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure932Total liabilities, Q1 FY2025, at 2025-03-31$932.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure879Total liabilities, Q2 FY2025, at 2025-06-30$878.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure834Total liabilities, Q3 FY2025, at 2025-09-30$834.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure633Total liabilities, FY2025, at 2025-12-31$633.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure1,019Total liabilities, Q1 FY2026, at 2026-03-31$1.02bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure1,012Total liabilities, Q2 FY2026, at 2026-06-30$1.01bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Long-term debt$m298Long-term debt, Q3 FY2023, at 2023-09-30$298.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2023-11-08, accession 0001628280-23-037847.Report this figure303Long-term debt, FY2023, at 2023-12-31$303.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2025-02-25, accession 0001628280-25-007715.Report this figure308Long-term debt, Q1 FY2024, at 2024-03-31$308.5m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-05-07, accession 0001628280-24-021069.Report this figure314Long-term debt, Q2 FY2024, at 2024-06-30$313.8m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-08-06, accession 0001628280-24-035170.Report this figure314Long-term debt, Q3 FY2024, at 2024-09-30$314.3m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure315Long-term debt, FY2024, at 2024-12-31$314.9m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure315Long-term debt, Q1 FY2025, at 2025-03-31$315.4m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure243Long-term debt, Q2 FY2025, at 2025-06-30$242.8m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure194Long-term debt, Q3 FY2025, at 2025-09-30$194.4m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure0.0Long-term debt, FY2025, at 2025-12-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure395Long-term debt, Q1 FY2026, at 2026-03-31$395.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure395Long-term debt, Q2 FY2026, at 2026-06-30$395.4m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure
Shareholders' equity$m(411)Shareholders' equity, Q3 FY2023, at 2023-09-30−$411.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure(456)Shareholders' equity, FY2023, at 2023-12-31−$455.5m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001628280-26-012240.Report this figure(476)Shareholders' equity, Q1 FY2024, at 2024-03-31−$476.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure(476)Shareholders' equity, Q2 FY2024, at 2024-06-30−$475.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure(469)Shareholders' equity, Q3 FY2024, at 2024-09-30−$468.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure(476)Shareholders' equity, FY2024, at 2024-12-31−$475.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure(452)Shareholders' equity, Q1 FY2025, at 2025-03-31−$451.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure(422)Shareholders' equity, Q2 FY2025, at 2025-06-30−$421.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure(388)Shareholders' equity, Q3 FY2025, at 2025-09-30−$387.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure(119)Shareholders' equity, FY2025, at 2025-12-31−$119.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure(554)Shareholders' equity, Q1 FY2026, at 2026-03-31−$553.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure(454)Shareholders' equity, Q2 FY2026, at 2026-06-30−$454.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure

Cash flow

Operating cash flow$104.3m, Q2 FY2026
Capital expenditure$209.0k, Q2 FY2026
Biocryst Pharmaceuticals Inc, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(19.9)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$19.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-05, accession 0001628280-24-045364. Derived: 9-month figure less the 6-month figure.Report this figure(8.9)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(53.7)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$53.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure(1.4)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-05, accession 0001628280-25-037795. Derived: 6-month figure less the 3-month figure.Report this figure8.2Operating cash flow, Q3 FY2024, three months to 2024-09-30$8.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001628280-25-048785. Derived: 9-month figure less the 6-month figure.Report this figure(5.2)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(27.5)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$27.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure41.3Operating cash flow, Q2 FY2025, three months to 2025-06-30$41.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053300. Derived: 6-month figure less the 3-month figure.Report this figure41.6Operating cash flow, Q3 FY2025, three months to 2025-09-30$41.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001628280-25-048785. Derived: 9-month figure less the 6-month figure.Report this figure292Operating cash flow, Q4 FY2025, three months to 2025-12-31$292.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure(61.8)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$61.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure104Operating cash flow, Q2 FY2026, three months to 2026-06-30$104.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001628280-26-053300. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m1.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$987.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2024-11-05, accession 0001628280-24-045364. Derived: 9-month figure less the 6-month figure.Report this figure0.6Capital expenditure, Q4 FY2023, three months to 2023-12-31$554.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$235.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure0.2Capital expenditure, Q2 FY2024, three months to 2024-06-30$155.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-08-05, accession 0001628280-25-037795. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$59.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-04, accession 0001628280-25-048785. Derived: 9-month figure less the 6-month figure.Report this figure0.7Capital expenditure, Q4 FY2024, three months to 2024-12-31$675.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$143.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure0.2Capital expenditure, Q2 FY2025, three months to 2025-06-30$179.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-08-05, accession 0001628280-26-053300. Derived: 6-month figure less the 3-month figure.Report this figure1.3Capital expenditure, Q3 FY2025, three months to 2025-09-30$1.3m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-04, accession 0001628280-25-048785. Derived: 9-month figure less the 6-month figure.Report this figure0.8Capital expenditure, Q4 FY2025, three months to 2025-12-31$802.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-02-26, accession 0001628280-26-012240. Derived: 12-month figure less the 9-month figure.Report this figure0.4Capital expenditure, Q1 FY2026, three months to 2026-03-31$403.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure0.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$209.0k. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2026-08-05, accession 0001628280-26-053300. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)265.17m, Q2 FY2026
Biocryst Pharmaceuticals Inc, shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares186Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30186,180,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-08, accession 0001628280-23-037847.Report this figure189Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31188,509,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001628280-24-021069.Report this figure189Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30189,118,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0001628280-24-035170.Report this figure190Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30189,644,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-05, accession 0001628280-24-045364.Report this figure206Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31206,064,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-06, accession 0001628280-25-022658.Report this figure206Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30206,425,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-05, accession 0001628280-25-037795.Report this figure207Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30206,905,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure215Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31215,261,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure220Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30219,886,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure220Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30219,885,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001628280-25-048785.Report this figure242Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31242,258,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-06, accession 0001628280-26-031238.Report this figure265Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30265,165,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure

Shares outstanding: 255.54mShares outstanding, period not labelled, at 2026-07-31255,535,105 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-05, accession 0001628280-26-053300.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. Listed shows no prices and gives no investment advice.